Quick Summary:
The biotechnology industry is ever-growing, with new advancements and developments shaping the future of healthcare. For businesses seeking insight and a competitive edge, the comprehensive financial and strategic SWOT Analysis Review of Kazia Therapeutics Ltd (KZA) is a must-have resource. Garnering not only an understanding of KZA's operations, but also their strengths, weaknesses, opportunities, and threats, this report is your tool towards informed decision-making, formulated strategies, and a deeper understanding of partners, customers, and competitors alike.
KZA focuses on anti-cancer drug development and works with renowned research institutes, hospitals, and universities. This profile unearths KZA's detailed business descriptions, corporate strategies, a five-year history of financial ratios and interim ratios, key competitors, and executive biographies among other essential data. Providing an unbiased view of the company's operations and trends, the profile allows for clear identification of potential customers, suppliers, and business strategies. Utilize this resource to amplify your industry insight and fortify your market position.
Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Kazia Therapeutics Ltd (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The company’s product pipeline includes paxalisib (formerly GDC-0084), Cantrixil (TRX-E-002-1) and EVT801. Paxalisib is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule that acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. EVT801 is a substance that blocks a cellular receptor called VEGFR3, which is responsible for the development of new blood and lymphatic vessels. The company has collaborations with various research institutes, hospitals, and universities including St Jude Children's Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.Kazia Therapeutics Ltd Key Recent Developments
- May 01023: Kazia Therapeutics: Appointment of chief executive officer; resignation of chief executive officer
- Jul 12022: Kazia launches new scientific advisory board comprised of world-leading experts in brain cancer
- Jun 13022: Positive Data for Paxalisib in Two Childhood Brain Cancers Presented at 20th Ispno Annual Meeting
- Jan 07022: Kazia Therapeutics to present at hc wainwright bioconnect conference
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Genentech USA Inc
- Biogen Inc
- Life Technologies Corp
- Cancure Ltd
- Prescient Therapeutics Ltd
- Gilead Sciences Ltd
- Amgen Inc